SFJ plays hardball, demands rights to PhaseBio's lead candidate

Paul Schloesser

Associate Editor

More than two and a half years after backing PhaseBio in developing a drug that can reverse a specific blood thinner, California-based SFJ Pharmaceuticals is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

SFJ plays hardball, demands rights to PhaseBio's lead candidate

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

SFJ plays hard­ball, de­mands rights to Phase­Bio's lead can­di­date

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

SFJ plays hardball, demands rights to PhaseBio's lead candidate